BRAIN AG. (7/2/20). "Press Release: BRAIN AG Purchases the Outstanding 24.7% Minority Stake of WeissBioTech GmbH". Zwingenberg.

	Organisation	BRAIN Biotechnology Reserarch and Information Network AG (FSE: BNN)
	Today	BRAIN Biotech AG
	Group	BRAIN Biotech (Group)
	Organisation 2	WeissBioTech GmbH
	Group	BRAIN Biotech (Group)
	Product	industrial enzyme
	Product 2	industrial biotechnology
	Person	Moelker, Adriaan (BRAIN 202002– CEO before Flint Group + AB Enzymes + Genencor + DSM)
	Person 2	Konle, Stephanie (BRAIN 202002– Managing Associate Corporate Communications before Weka Business Medien + Merck)

B.R.A.I.N. Biotechnology Research and Information Network AG announces today the purchase of the outstanding 24.7% minority stake of WeissBioTech GmbH from founder Hans de Bie. Terms and conditions of the deal will not be publicly disclosed.

In 2014 BRAIN AG made a strategic investment into WeissBioTech to gain access to the growing and profitable enzyme market. Since then, BRAIN AG and WeissBioTech have worked closely together to discover, develop and sell innovative enzyme products and solutions for customers worldwide.

In 2018, BRAIN AG made another key strategic move through its acquisition of Biocatalysts Ltd. in Cardiff, UK, an enzyme company with strong fermentation technology and enzyme R&D, serving specialty niche markets. Together with BRAIN's extensive enzyme technology skills, the WeissBioTech and Biocatalysts capabilities will form a solid platform for strong growth in the specialty enzymes business.

Adriaan Moelker, CEO BRAIN AG, states: “We are continuously working to build and optimize the group structure as announced during our capital increase in June, 2020. The full acquisition and integration of WeissBioTech GmbH gives us important flexibility to optimize our production network and capture synergies within the group. I would particularly like to thank founder Hans de Bie for his significant contribution to the development of the company - and Lukas Linnig at BRAIN who made this agreement come to fruition. Ultimately, all our stakeholders will benefit from this transaction.“

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this “Toolbox of Nature” are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN’s business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the “Tailor-Made Solutions” cooperation business), and the company’s own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at www.brain-biotech.com.

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Media Contact

Dr. Stephanie Konle
pr@brain-biotech.com
+49 (0)6251-9331-70

Record changed: 2023-06-05